Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model

Archives of Ophthalmology

Volumn 121, Issue 5, 2003, Pages 626-630

  Abelson, Mark B ^a,b   Chapin, Matthew J ^b   Kapik, Barry M ^c   Shams, Naveed B K ^c  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b Ophthalmic Research Associates   (United States)

^c Novartis Ophthalmics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETOTIFEN FUMARATE; PLACEBO;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAST CELL DEGRANULATION; PREVALENCE; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEASONAL VARIATION; SINGLE BLIND PROCEDURE;

ADULT; AGED; ALLERGENS; ANTI-ALLERGIC AGENTS; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPEREMIA; KETOTIFEN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OPHTHALMIC SOLUTIONS; PRURITUS; SAFETY;

EID: 0037653687     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.5.626     Document Type: Article

References (17)

1. Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy. 1987;21:1-20.
2. Allansmith MR, Ross RN. Ocular allergy. Clin Allergy. 1988;18:1-13.
3. Abelson MB, Chapin MJ. Current and future topical treatments for ocular allergy. Compr Ophthalmol Update. 2000;1:303-320.
4. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther. 2000;22:826-833.
5. Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs. 1990;40:412-448.
6. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge: a clinical approach to studying allergic conjunctivitis. Arch Ophthalmol. 1990;108:84-88.
7. Greiner JV, Abelson MB, DuBiner H, et al. A randomized, double-masked, placebo-controlled, efficacy and safety study of ketotifen fumarate 0.025%. Paper presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; April 29-May 4, 2001; Ft Lauderdale, Fla. Abstract 4878-B897.
8. Reaves AT, Abelson MB, Mundorf TK, et al. Two randomized, double-masked, placebo-controlled single-dose efficacy and safety studies of ketotifen fumarate 0.025%. Paper presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; April 29-May 4, 2001; Ft Lauderdale, Fla. Abstract 4886-B905.
9. Hugues FC, Le Jeunne C. Systemic and local tolerability of ophthalmic drug formutations: an update. Drug Saf. 1993;8:365-380.
10. Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol. 1981;99:302-304.
11. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol. 1993;38(suppl):115-132.
12. Abelson MB, Lanier RQ. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Acta Ophthalmol Scand Suppl. 1999;228:53-56.
13. Deschenes J, Discepola M, Abelson M. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol Scand Suppl. 1999;228:47-52.
14. Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol. 2000;130:717-723.
15. Berdy GJ. Atopic keratoconjunctivitis (AKC). Acta Ophthal mol Scand Suppl. 1999;228:7-9.
16. Nabe M, Miyagawa H, Agrawal DK, Sugiyama H, Townley RG. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis. Allergy Proc. 1991;12:267-271.
17. Devillier P, Arnoux B, Lalau Keraly C, Landes A, Marsac J, Benveniste J. Inhibition of human and rabbit platelet activation by ketotifen. Fundam Clin Pharmacol. 1990;4:1-9.